Original language | English |
---|---|
Journal | SKIN: Journal of Cutaneous Medicine |
Volume | 6 |
Issue number | 2 |
DOIs |
|
State | Published - 4 Mar 2022 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: SKIN: Journal of Cutaneous Medicine, Vol. 6, No. 2, 04.03.2022.
Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - Tapinarof Cream 1% Once Daily for Plaque Psoriasis
T2 - Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent
AU - Strober, Bruce
AU - Gold, Linda Stein
AU - Bissonnette, Robert
AU - Armstrong, April
AU - Blauvelt, Andrew
AU - Kircik, Leon
AU - Brown, Philip M.
AU - Tallman, Anna M.
AU - Lebwohl, Mark
N1 - Funding Information: This study was funded by Dermavant Sciences, Inc. The authors thank the participating investigators, patients and their families, and colleagues involved in the onduct of the study. B.S. has served as an honorary consultant/speaker/scientific director/investigator for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol-Myers-Squibb, Cara, Celgene, Corrona Psoriasis Registry, Dermavant Sciences Inc., Dermira, Equillium, Janssen, Leo, Eli Lilly, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron and Sanofi-Genzyme. L.S.G as served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. R.B. has served as a consultant/advisory oard member/speaker/investigator, and/or receives honoraria/grant from Almirall, Amgen, AnaptysBio, Arcutis, Arena Pharma, Aristea, Asana BioSciences, Bausch Health, Bellus Health, Bluefin Biomedicine, Boehringer-Ingelheim, Bristol-Myers Squibb, CARA, Dermavant Sciences Inc., Eli Lilly, EMD Serono, Escalier, Evidera, Galderma, GSK, Inmagene Bio, Incyte, Janssen, Kiniksa, Kyowa Kirin, LEO Pharma, Nimbus, Novan, Pfizer, Ralexar, RAPT, Regeneron, Respivant, Sanofi Genzyme, Sienna, Target RWE, and UCB. R.B. is an employee and shareholder of Innovaderm Research. AM is a research investigator and/ r scientific advisor to AbbVie, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant Sciences Inc., Dermira, Sanofi, Regeneron, Pfizer, and Modmed. A.B. has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, eo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. L.K. has served as a consultant/speaker/investigator/advisory board member for Abbott Laboratories, AbbVie, Ablynx, Aclaris, Acambis, Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Anaptys, Arcutis, Arena, Assos Pharma, Astellas Pharma US, Inc., Asubio, Bausch Health, Berlex Laboratories (Bayer HealthCare Pharmaceuticals), Biogen-Idec, Biolife, Biopelle, BMS, Boehringer-Ingleheim, Breckinridge Pharma, Cassiopea, Centocor, Inc., Cellceutix, Cipher, Coherus, Colbar, Combinatrix, Connetics Corporation, Coria, Dermavant Sciences Inc, Dermira, Dermik Laboratories, Dow Pharmaceutical Sciences, Inc., Dr. Reddy’s Lab, Dusa, Embil Pharmaceuticals, Eli Lilly, EOS, Exeltis, Ferndale Laboratories, Inc., Foamix, Ferrer, Galderma, Genentech, Inc., GlaxoSmithKline, PLC, Glenmark, Health Point, LTD, Idera, Incyte, Intendis, nnocutis, Innovail, Isdin, Johnson & Johnson, Kyowakirin, Laboratory Skin Care Inc., Leo Pharma, L’Oreal, 3M, Maruho, Medical International Technologies, Merck, Medicis Pharmaceutical Corp., Merz, Nano Bio, Novartis AG, Nven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, PediaPharma, Pfizer, Promius, PuraCap, PharmaDerm, QLT, Inc, Quinnova, Quatrix, Regeneron, Sanofi, Serono (Merck Serono International SA), SkinMedica, nc., Stiefel Laboratories, Inc., Sun Pharma, Taro, TolerRx, Triax, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort, and ZAGE. P.M.B. and A.N.T. are mployees of Dermavant Sciences Inc., with stock options. M.L. has received grants, and/or is a consultant for AbbVie, Amgen, Aditum Bio, Almirall, AltruBio nc., AnaptysBio, Arcutis, Aristea Therapeutics, Arrive Technologies, Avotres, BiomX, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Dr. Reddy’s Laboratories, Eli Lilly, Evelo Biosciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., Incyte, Janssen Research & Development, LEO Pharma, LLC, Meiji Seika Pharma, Mindera, Ortho Dermatologics, Pfizer, Regeneron, Seanergy, UCB, Inc., and Verrica. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Contact Dr Bruce Strober at [email protected] with questions or comments. Funding Information: This study was funded by Dermavant Sciences, Inc. The authors thank the participating investigators, patients and their families, and colleagues involved in the conduct of the study. B.S. has served as an honorary consultant/speaker/scientific director/investigator for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol-Myers-Squibb, Cara, Celgene, Corrona Psoriasis Registry, Dermavant Sciences Inc., Dermira, Equillium, Janssen, Leo, Eli Lilly, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron and Sanofi-Genzyme. L.S.G has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. R.B. has served as a consultant/advisory board member/speaker/investigator, and/or receives honoraria/grant from Almirall, Amgen, AnaptysBio, Arcutis, Arena Pharma, Aristea, Asana BioSciences, Bausch Health, Bellus Health, Bluefin Biomedicine, Boehringer-Ingelheim, Bristol-Myers Squibb, CARA, Dermavant Sciences Inc., Eli Lilly, EMD Serono, Escalier, Evidera, Galderma, GSK, Inmagene Bio, Incyte, Janssen, Kiniksa, Kyowa Kirin, LEO Pharma, Nimbus, Novan, Pfizer, Ralexar, RAPT, Regeneron, Respivant, Sanofi Genzyme, Sienna, Target RWE, and UCB. R.B. is an employee and shareholder of Innovaderm Research. AM is a research investigator and/ or scientific advisor to AbbVie, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant Sciences Inc., Dermira, Sanofi, Regeneron, Pfizer, and Modmed. A.B. has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. L.K. has served as a consultant/speaker/investigator/advisory board member for Abbott Laboratories, AbbVie, Ablynx, Aclaris, Acambis, Allergan, Inc., Almirall, Amgen, Inc., Anacor Pharmaceuticals, Anaptys, Arcutis, Arena, Assos Pharma, Astellas Pharma US, Inc., Asubio, Bausch Health, Berlex Laboratories (Bayer HealthCare Pharmaceuticals), Biogen-Idec, Biolife, Biopelle, BMS, Boehringer-Ingleheim, Breckinridge Pharma, Cassiopea, Centocor, Inc., Cellceutix, Cipher, Coherus, Colbar, Combinatrix, Connetics Corporation, Coria, Dermavant Sciences Inc, Dermira, Dermik Laboratories, Dow Pharmaceutical Sciences, Inc., Dr. Reddy’s Lab, Dusa, Embil Pharmaceuticals, Eli Lilly, EOS, Exeltis, Ferndale Laboratories, Inc., Foamix, Ferrer, Galderma, Genentech, Inc., GlaxoSmithKline, PLC, Glenmark, Health Point, LTD, Idera, Incyte, Intendis, Innocutis, Innovail, Isdin, Johnson & Johnson, Kyowakirin, Laboratory Skin Care Inc., Leo Pharma, L’Oreal, 3M, Maruho, Medical International Technologies, Merck, Medicis Pharmaceutical Corp., Merz, Nano Bio, Novartis AG, Nven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, PediaPharma, Pfizer, Promius, PuraCap, PharmaDerm, QLT, Inc, Quinnova, Quatrix, Regeneron, Sanofi, Serono (Merck Serono International SA), SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, TolerRx, Triax, UCB, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort, and ZAGE. P.M.B. and A.N.T. are employees of Dermavant Sciences Inc., with stock options. M.L. has received grants, and/or is a consultant for AbbVie, Amgen, Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Aristea Therapeutics, Arrive Technologies, Avotres, BiomX, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Dr. Reddy’s Laboratories, Eli Lilly, Evelo Biosciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., Incyte, Janssen Research & Development, LEO Pharma, LLC, Meiji Seika Pharma, Mindera, Ortho Dermatologics, Pfizer, Regeneron, Seanergy, UCB, Inc., and Verrica. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464).
PY - 2022/3/4
Y1 - 2022/3/4
UR - http://www.scopus.com/inward/record.url?scp=85136435476&partnerID=8YFLogxK
U2 - 10.25251/skin.6.supp.5
DO - 10.25251/skin.6.supp.5
M3 - Comment/debate
AN - SCOPUS:85136435476
SN - 2574-1624
VL - 6
JO - SKIN: Journal of Cutaneous Medicine
JF - SKIN: Journal of Cutaneous Medicine
IS - 2
ER -